Search results for: 'risk'

This research service offers a comprehensive analysis of the global genetic testing industry (specifically, germline genetic testing, which analyzes inherited genetic variations present in an individual from birth and can be passed to offspring). The industry growth is driven by a shift towards preventive care, rising maternal ages, increasing gove...

Cardiovascular diseases (CVDs) remain the leading cause of global morbidity and mortality, with reported cases having doubled since 1990. Today, CVDs account for 1 in 3 deaths worldwide, representing 32% of total global mortality, with heart attacks and ischemic strokes responsible for approximately 85% of these outcomes. The rising burden is stron...

The main objective of this research is to estimate test volumes and unit prices for a wide variety of LDTs (genetic) and a few high volume FDA tests for selective therapeutic areas. The tests are categorized by their intended uses across the diagnostic spectrum (risk assessment, screening, diagnosis, staging and prognosis, therapy selection, therap...

19 Feb 2025  |  Global  |  Market Research

Antimicrobial Resistance Diagnostics Market, Global, 2024–2030

The Shift to Whole-genome Sequencing and Multiplex Point-of-care Testing is Driving Transformational Growth Due to Improved Speed, Accuracy, and High Throughput

Infographics

×

This Frost & Sullivan report examines the antimicrobial resistance (AMR) diagnostics market in human health. AMR, characterized by bacteria, viruses, and fungi that no longer respond to antimicrobial medications, is one of the top ten global public health threats. When pathogens develop drug resistance, medications become ineffective, leading to in...

The SCOPE Summit 2026, held in Orlando, Florida, from February 2 to 5, 2026, highlighted the dominance of small- to mid-segment companies and specialized CROs focusing on specific therapy areas or aspects of clinical trials, such as bioanalysis. With more than 4,000 attendees, 630 speakers, and 300 exhibitors, SCOPE 2026 reinforced its position as ...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations transforming respiratory medicine, liver regeneration, metabolic disease management, infectious disease therapeutics, neurological disorders, cardiovascular risk reduction, oncology workflows, and nex...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping drug discovery, diagnostics, and therapeutic delivery across oncology, infectious diseases, rare and metabolic disorders, neuromuscular and neurodegenerative conditions, diabetes, ophthalmol...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping biomanufacturing, cell and gene therapy, precision immunotherapy, anti-infectives, and neurotherapeutics across oncology, infectious disease, nephrology, and neurodegenerative disease. It hi...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations transforming AI-enabled discovery, precision diagnostics, cell engineering, targeted therapeutics, vaccines, and skin health across oncology, metabolic disease, rare disorders, neuropsychiatry, and ne...